Protox Therapeutics Inc. (Protox) is a biopharmaceutical company focused on the research, development and commercialization of receptor targeted fusion proteins for the treatment of human diseases. These fusion proteins are designed to deliver potent payloads to tissues or cells to either cause cell death or promote survival without the side-effects normally associated with conventional therapeutics. Protox is developing three complementary technology platforms: PORxin, INxin and HUMxin. The Company’s PORxin candidate, PRX302 is in two separate Phase 2 clinical trials for the treatment of benign prostatic hyperplasia. The INxin candidate, PRX321, has been evaluated in 86 patients with primary brain cancer and other solid tumors. HUMxin is a program to develop receptor targeted fusion proteins. In January 2009, a multi-centre, double-blinded, placebo controlled Phase 2 study of PRX302 was initiated in subjects with moderate to severe BPH.